• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease

byCaitlyn HuiandDeepti Shroff Karhade
December 10, 2018
in Chronic Disease, Gastroenterology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The biosimilar to infliximab, CT-P13 was shown in this study to have equivalent efficacy to the anti tumor-necrosis factor (TNF) monoclonal antibody for Crohn’s treatment.

2. There was no significant safety differences observed in this study between the two treatments for Crohn’s disease.

Evidence Rating Level: 2 (Good)

Study Rundown: Crohn’s disease is managed by a variety of different treatment options, including the anti-TNF monoclonal antibody known as infliximab. The authors of this study investigated the effectiveness and safety of a new treatment option, CT-P13, which is a biosimilar of the reference product infliximab. A similar safety and efficacy was observed in the biosimilar to infliximab for the treatment of Crohn’s disease. The main limitation of this study was that the authors used proxies to estimate disease severity, since the database utilized in the cohort study did not include all the relevant clinical data necessary for certain clinical indices of Crohn’s. Overall, the study results suggested that the biosimilar CT-P13 is comparable to infliximab.

Click to read the study in Annals of Internal Medicine

Relevant Reading: Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

RELATED REPORTS

Fecal calprotectin is a useful marker for defining small bowel endoscopic remission in Crohn’s disease

Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis

Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn’s disease

In-Depth [comparative equivalence cohort study]: The authors of this study conducted a comparative equivalence cohort study to compare the biosimliar CT-P13 to infliximab, an anti-TNF monoclonal antibody, with regards to safety and efficacy of managing Crohn’s disease. The sample size was calculated with an expected event rate of 40% in each treatment group – patients naïve to infliximab treated with the biosimilar versus infliximab. The main endpoints were composite end point of death, Crohn’s-disease related surgery, all-cause hospitalization and reimbursement of another biologic therapy. There were no safety differences in outcomes observed between the two groups, including differences in serious infections (HR, 0.82 [CI, 0.61 to 1.11]) and tuberculosis (HR, 1.10 [CI, 0.36 to 3.34]). Furthermore,  CT-P13 was found to be equivalent to infliximab in a multivariate analysis (HR, 0.92 [95% CI, 0.85-0.99]) of the primary outcome.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: biosimilarCPCrohn's DiseaseInfliximab
Previous Post

Quick Take: Analgesic efficacy and safety of morphine in the Procedural Pain in Premature Infants (Poppi) study: randomised placebo-controlled trial

Next Post

Study finds that pediatric residents rarely perform neonatal intubation

RelatedReports

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Fecal calprotectin is a useful marker for defining small bowel endoscopic remission in Crohn’s disease

July 7, 2025
Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis

June 9, 2025
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn’s disease

May 14, 2025
Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

April 17, 2025
Next Post
AAP addresses neonatal pain prevention

Study finds that pediatric residents rarely perform neonatal intubation

Corticosteroids improve outcomes in treatment of community-acquired pneumonia

Veteran Health hospitals consistently outperform non-Veteran Health hospitals in several measures of quality of care

Engineered stem cells mitigate liver damage caused by radiation [PreClinical]

2 Minute Medicine Rewind December 11, 2018

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
  • Structured exercise intervention improves survival in colon cancer patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.